NHS Weight Loss Injections Eligibility UK: BMI Criteria, Tier 3 Pathway & How to Get Referred

Access to NHS-funded weight loss injections (principally Wegovy/semaglutide and Mounjaro/tirzepatide at the time of writing) is governed by NICE (National Institute for Health and Care Excellence) technology appraisals. These set out specific eligibility criteria that must be met for NHS prescribing.

Core NICE BMI Criteria:

• •BMI of 35 kg/m² or above with at least one weight-related comorbidity (see below), OR
• •BMI of 30 kg/m² or above in certain higher-risk groups, including those of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family background (where lower BMI thresholds reflect higher metabolic risk)

Weight-Related Comorbidities That Count: Having at least one of the following alongside the BMI threshold is typically required: - Type 2 diabetes or pre-diabetes (impaired fasting glucose / impaired glucose tolerance) - Hypertension (high blood pressure) - Dyslipidaemia (abnormal cholesterol or triglyceride levels) - Obstructive sleep apnoea - Non-alcoholic fatty liver disease (NAFLD) - Polycystic ovary syndrome (PCOS) - Cardiovascular disease (for semaglutide specifically, which has proven cardioprotective effects) - Osteoarthritis affecting mobility and quality of life

Additional Requirements: - Must have been unable to achieve significant weight loss through diet and exercise alone, typically evidenced by engagement with Tier 1 and Tier 2 interventions - The medication is intended as an adjunct to a reduced-calorie diet and increased physical activity — not as a standalone treatment

*Individual ICB (Integrated Care Board) criteria may vary. Always confirm with your GP or specialist.*

Two key NICE technology appraisals govern NHS access to the most effective weight loss injections currently available in the UK.

NICE TA875 — Semaglutide (Wegovy) for Weight Management: Published in March 2023, TA875 recommended Wegovy as an option for weight management in adults with: - BMI ≥35 kg/m² and at least one weight-related condition, OR BMI ≥30 kg/m² in higher-risk ethnic groups - Engagement with a specialist weight management service (Tier 3) - Use for a maximum of 2 years under current NHS guidance (reflecting the cost-effectiveness assessment period)

TA875 was a landmark decision — it was the first NICE approval of a highly effective weight loss medication since orlistat, and it represented a significant acknowledgement of obesity as a chronic disease requiring medical treatment.

NICE TA924 — Tirzepatide (Mounjaro) for Weight Management: Published in 2024, TA924 recommended Mounjaro as an option for weight management under broadly similar criteria to TA875. Tirzepatide has demonstrated superior weight loss outcomes compared to semaglutide in head-to-head trials (SURMOUNT-5), achieving 20%+ body weight reduction at the highest doses.

What These Appraisals Mean in Practice: - NHS funding is available but access is not automatic - Both medications are commissioned through specialist weight management services (Tier 3), not typically by GPs prescribing independently - ICBs vary significantly in how quickly they have implemented these appraisals — some have well-developed pathways, others are still in development - The 2-year treatment duration limit in current guidance means ongoing access for longer-term treatment is still under review by NICE

*NICE guidelines are regularly updated. Check the NICE website (nice.org.uk) for the most current versions of TA875 and TA924.*

The NHS organises weight management services into a tiered framework. To access Tier 3 specialist services — where weight loss injections are prescribed — patients are generally expected to have progressed through (or at least been offered) lower tier interventions.

Tier 1 — Community and Self-Help: - Public health campaigns and community-based programmes - Weight Watchers / Slimming World referrals (some GPs can refer free of charge) - NHS Better Health resources and digital tools - Physical activity referrals

These require no formal referral and are the entry point for most people.

Tier 2 — Primary Care Supported Lifestyle Intervention: - Structured, time-limited weight management programmes delivered in primary care or community settings - Typically involves a dietitian or health coach, with regular check-ins over 12 weeks - Low-calorie diet programmes (sometimes including Total Diet Replacement for people with very high BMIs) - Often commissioned through your GP practice or ICB - Important: Documenting your engagement with Tier 2 services strengthens any case for Tier 3 referral

Tier 3 — Specialist Multi-Disciplinary Weight Management Service: - Hospital or community-based specialist service involving a multi-disciplinary team (MDT): often including a doctor (usually an endocrinologist or bariatric physician), specialist dietitian, psychologist, and physiotherapist - Comprehensive medical assessment, including investigation of underlying causes of obesity - Prescription of weight management medications, including Wegovy and Mounjaro under NICE guidance - Preparation and follow-up for bariatric surgery (Tier 4) - This is where NHS access to weight loss injections occurs

Tier 4 — Bariatric Surgery: For patients meeting stricter criteria, where lifestyle and medical interventions have not achieved adequate results.

*Progress through the tiers is not always strictly linear — your GP can refer directly to Tier 3 if clinically appropriate.*

Many people who would benefit from NHS weight loss treatment don't receive it because they don't know how to effectively advocate for themselves in a GP consultation. The following guidance is designed to help you have a productive conversation.

Before the Appointment: - Calculate your BMI using an NHS-approved tool or app. Record your height and weight accurately. - List your comorbidities — any conditions related to your weight (type 2 diabetes, hypertension, sleep apnoea, PCOS, etc.) - Document previous weight loss attempts — diet programmes, exercise regimes, Tier 2 services, any medications tried (e.g. orlistat). The more evidence of genuine effort you can provide, the stronger your case. - Note the impact on your daily life — mobility, mental health, quality of life, ability to work

During the Appointment: - Be direct: *"I'd like to discuss a referral to the specialist weight management service for medical weight management, including potential eligibility for NICE-approved weight loss medication."* - Mention the specific NICE appraisals by name (TA875 for Wegovy, TA924 for Mounjaro) if your GP appears unfamiliar — this is helpful context - Ask specifically about Tier 3 referral and what the local pathway looks like - If told there is a waiting list, ask to be added and confirm the expected timeframe

If Your GP Declines: - Ask for the reason in writing - Ask what criteria you would need to meet for a referral to be appropriate - You are entitled to a second opinion from another GP within your practice or a different surgery - Contact your ICB patient services if you believe you meet the criteria and feel your referral is being inappropriately withheld

*GPs have clinical discretion and local commissioning constraints. Being informed, prepared, and polite maximises your chances of a productive outcome.*

One of the most significant frustrations for eligible patients is the variation in waiting times across England, Wales, Scotland, and Northern Ireland. The implementation of NICE TA875 and TA924 has not been uniform, and demand has substantially outstripped capacity in many areas.

England: Waiting times for Tier 3 specialist weight management services vary dramatically by Integrated Care Board (ICB). As of early 2026: - Best-performing areas (e.g. some London and Greater Manchester ICBs with established services): 3–6 months - Average wait: 9–18 months in many areas - Worst-performing areas: 2+ years in some ICBs with limited commissioned Tier 3 capacity

The NHS 'Right to Choose' policy may allow patients in some areas to access Tier 3 services at alternative providers if their local wait exceeds 18 weeks — ask your GP whether this applies in your ICB.

Scotland: Scottish Medicines Consortium (SMC) has approved both semaglutide and tirzepatide. Access through NHS Scotland is developing, with some Health Boards having more established pathways than others. Check with your GP practice for local availability.

Wales: All Wales Medicines Strategy Group (AWMSG) has reviewed GLP-1 medications for weight management. Access varies by health board, with waiting times broadly similar to England.

Northern Ireland: Implementation is ongoing. Speak to your GP for up-to-date information on local pathways.

What You Can Do While Waiting: - Continue engaging with Tier 1 and Tier 2 interventions — this strengthens your referral case and provides real benefit - Ask to be placed on the waiting list as soon as possible - Keep your GP updated about any changes in your health status that might increase clinical urgency

*Waiting time data changes frequently. Your GP and ICB website will have the most current information for your area.*

For many people, NHS waiting times are a significant barrier — and private prescribing of weight loss injections has grown substantially since the NICE approvals of Wegovy and Mounjaro. Understanding the private landscape allows you to make an informed decision.

Private Wegovy and Mounjaro Costs in the UK (Approximate 2026 Prices): - Wegovy (semaglutide): £150–£300 per month depending on dose and provider - Mounjaro (tirzepatide): £130–£250 per month depending on dose and provider - Consultation fees: £50–£150 for initial consultation; some providers include this in a subscription - Annual cost at maintenance dose: approximately £1,800–£3,600 for either medication

Types of Private Providers:

1. Online weight management clinics — platforms such as those partnering with registered UK doctors. Convenient, fast, often cheaper. Key considerations: - Ensure the provider is CQC-registered (Care Quality Commission) if England-based - Prescribers should be GMC-registered doctors or GPhC-registered pharmacist prescribers - Look for providers that offer ongoing clinical review, not just a one-off prescription

2. Private hospital or specialist clinic — more comprehensive assessment, higher cost. Appropriate for those with complex comorbidities.

3. Private GP — some private GPs prescribe these medications as part of a wider health consultation.

Questions to Ask Any Private Provider: - Is the prescriber GMC or GPhC registered? - Is the service CQC-registered? - What monitoring and follow-up is included? - How do they handle side effects or complications? - What happens if the medication is unavailable due to supply issues?

An Important Note on Safety: Private prescribing is legal and safe when conducted by qualified clinicians, but the increase in online services has also led to a growth in unregulated, unsafe providers offering prescription medications without adequate clinical assessment. Always verify credentials before purchasing.

*This article is for informational purposes only and does not constitute medical advice. NHS and private eligibility should be discussed with a qualified healthcare professional. Never purchase weight loss injections without a valid UK prescription from a registered prescriber.*